Clinical Trial Update: Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating rifaximin versus no intervention for IgA monoclonal gammopathy of undetermined significance; currently recruiting at Fred Hutc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Monoclonal Gammopathy of Undetermined Significance

Drugs mentioned

• Xifaxan (rifaximin) (rifaximin)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: IgA Monoclonal Gammopathy of Undetermined Significance | Phase 2 | Status: RECRUITING